Skip to main content

Flavia H. Pease

Equibles does not estimate personal net worth.

Get an email with a short summary when Insulet Corp publishes a filing, an earnings call transcript or a press release.

Get PODD alerts

About Flavia H. Pease

Flavia H. Pease is recorded as CFO at Insulet Corp (PODD) since September 30, 2025. Charles River Laboratories International, Inc. reported in an 8-K filed September 16, 2025 that Flavia H. Pease resigned as Corporate Executive Vice President, Chief Financial Officer, effective September 29, 2025. Insulet Corp reported in an 8-K filed September 16, 2025 that Flavia H. Pease resigned as Board of Directors. Insulet Corp reported in an 8-K filed September 16, 2025 that Flavia H. Pease was appointed Executive Vice President and Chief Financial Officer, effective September 30, 2025. Flavia H. Pease has spoken on 2 earnings calls across 1 company, most recently for Insulet Corp on November 4, 2026. Insulet Corp is classified in the Medical Devices industry within the Healthcare sector. Other leadership on record at Insulet Corp includes Ashley A. McEvoy (CEO and Board Member), Ashley McEvoy (CEO and Board Member), Timothy J. Scannell (Chairman) and 7 others.

“On September 12, 2025, Flavia H. Pease informed Charles River Laboratories International, Inc. (the "Company") of her intention to resign from her position as the Company's Corporate Executive Vice President, Chief Financial Officer effective on September 29, 2025.”
Charles River Laboratories International, Inc. Form 8-K, filed September 16, 2025 · Read the filing
“In connection with her appointment as Executive Vice President and Chief Financial Officer, Ms. Pease has notified us that she will resign from the Board of Directors of the Company, effective on the day she begins employment with the Company.”
Insulet Corp Form 8-K, filed September 16, 2025 · Read the filing

Flavia H. Pease on recent calls

“The Inflat team delivered another strong quarter with total revenue of $842 million, an increase of 19.2% on a reported basis and 19.6% on a constant currency basis.”
CFO, Q3 2026 Insulet Corporation Earnings Call ·
“During the quarter, total Omnipod grew 31.3% on a constant currency basis. We generated total revenue of over $2.7 billion in 2025, an increase of 30.7% at reported rates and 29.5% at constant currency rates.”
CFO, Insulet Corp Q4 FY2025 Earnings Call ·

Affiliation history

Company network

Leadership on record at Insulet Corp

Recent activity